BIVV001 Fusion Protein as Factor VIII Replacement Therapy for Hemophilia A

BIVV001 Fusion Protein as Factor VIII Replacement Therapy for Hemophilia A: Severe hemophilia A (defined as Prophylaxis with factor VIII products that have an extended half-life has advanced the treatment of severe hemophilia, in part by improving the control of bleeding, joint health, and quality of life, and by reducing treatment burden. However, residual burden still…